Chemistry:Docirbrutinib
From HandWiki
Docirbrutinib is an investigational new drug that is being evaluated for the treatment of cancer. It is a selective Bruton's tyrosine kinase (BTK) inhibitor that targets chronic lymphocytic leukemia (CLL) and other B-cell malignancies.[1]
References
- ↑ "Discovery of AS-1763: A Potent, Selective, Noncovalent, and Orally Available Inhibitor of Bruton's Tyrosine Kinase". Journal of Medicinal Chemistry 64 (19): 14129–14141. October 2021. doi:10.1021/acs.jmedchem.1c01279. PMID 34529443.
 |  |
